trending Market Intelligence /marketintelligence/en/news-insights/trending/SqJPf78XX9P5Pof3Lw58WA2 content esgSubNav
In This List

United Therapeutics postpones US launch of implantable pump

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


United Therapeutics postpones US launch of implantable pump

United Therapeutics Corp. postponed the U.S. launch of its RemoSynch implantable pump for use with the Remodulin therapy for treating pulmonary arterial hypertension.

The system will now be available in 2018 due to regulatory delays. The company developed the RemoSynch system with Medtronic Inc.'s proprietary intravascular infusion catheter, implantable infusion pump and related infusion system components to deliver the drug to treat patients.

United Therapeutics and Medtronic are pursuing parallel regulatory filings for the device and the treatment.